University of North Carolina

PDS Biotechnology Announces Details of Virtual KOL Event

Retrieved on: 
Venerdì, Maggio 3, 2024
University, HNSCC, Section, Pembrolizumab, MD, PDSB, University of North Carolina, KOL, Biotechnology, Patient, Principal, PDS, Harvard Medical School, Immune system, Dana–Farber Cancer Institute, Q&A, Vaccine

PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced additional details of its virtual Key Opinion Leader (KOL) event to be held on Wednesday, May 8, 2024 at 1:30 PM ET.

Key Points: 
  • PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced additional details of its virtual Key Opinion Leader (KOL) event to be held on Wednesday, May 8, 2024 at 1:30 PM ET.
  • To register for the event, click here .
  • The virtual webinar will focus on the positive, updated data from the Company’s VERSATILE-002 Phase 2 clinical trial, current unmet need in HPV-positive head and neck cancer, and next steps for PDS Biotech’s planned triple combination trial including Versamune® HPV and PDS01ADC (IL-12 fused antibody drug conjugate).
  • The VERSATILE-002 trial (NCT04260126) is evaluating Versamune® HPV in combination with the immune checkpoint inhibitor (“ICI”) KEYTRUDA® (pembrolizumab) in patients with unresectable, recurrent, or metastatic HPV16-positive HNSCC.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

Retrieved on: 
Giovedì, Maggio 2, 2024
Johns Hopkins University, University, Mayo Clinic, Cancer, SOS, American College, Case Western Reserve University, AUC, ACG, Esophageal cancer, Prevalence, Methylation, Risk, Barrett's esophagus, Cleveland Clinic, American Journal, Lucid, Adenocarcinoma, National Cancer Institute, NPV, NGS, University of North Carolina, Gold, Detection, EGD, Patient, Research report, NCI, PPV, Medicare, Manuscript, GERD, Guideline, Gastroesophageal reflux disease, Medical imaging

NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device. This case-control study, led by Case Western Reserve University's Amitabh Chak, M.D., was funded through the NCI's Barrett's Esophagus Translational Research Network (BETRNet), and included renowned investigators from leading academic medical centers, including Case Western Reserve University, Mayo Clinic, Johns Hopkins University, Washington University in St. Louis, University of North Carolina, and Cleveland Clinic. EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD). The manuscript, entitled Multicenter, Prospective Trial of Non-Endoscopic Biomarker-Driven Detection of Barrett's Esophagus And Esophageal Adenocarcinoma, was published in the American Journal of Gastroenterology, the leading clinical journal covering gastroenterology published on behalf of the American College of Gastroenterology (ACG).

Key Points: 
  • EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD).
  • Dr. Aklog concluded, "The publication of the BETRNet study is the culmination of a period of rapid expansion of EsoGuard's clinical evidence base.
  • It represents the second peer-reviewed, and third overall, clinical validation study demonstrating consistently excellent EsoGuard performance.
  • Soon to be released data from a fourth such clinical validation study tells the same story.

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Retrieved on: 
Martedì, Aprile 23, 2024
University, HNSCC, Section, Pembrolizumab, PDSB, University of North Carolina, KOL, Biotechnology, Patient, Principal, Immune system, Clinical trial, Pharmaceutical industry

PRINCETON, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced a Key Opinion Leader (“KOL”) Event to discuss positive, updated data from its VERSATILE-002 Phase 2 clinical trial with Versamune® HPV in combination with KEYTRUDA® (pembrolizumab) (NCT04260126) and next steps for Versamune® HPV and PDS01ADC. The new data cut-off from VERSATILE-002 clinical trial remains consistent with the update provided by PDS Biotech in October of 2023.

Key Points: 
  • The new data cut-off from VERSATILE-002 clinical trial remains consistent with the update provided by PDS Biotech in October of 2023.
  • The topline results to be discussed at the upcoming event are based on analysis of the most recent data cut-off.
  • “Approximately 20% of HPV-related patients with HNSCC will develop recurrent, incurable disease,” said Dr. Weiss.
  • “HPV-related HNSCC that is recurrent or metastatic is a devastating, difficult-to-treat cancer, and a majority of patients do not respond to current treatments, and therefore have a relatively short survival.

ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies for HIV Cure

Retrieved on: 
Venerdì, Aprile 19, 2024
Infection, ChAdOx1, HIV/AIDS, University, Bangladesh Technical Education Board, Cell, Gilead Sciences, Safety, CD4, Tissue, University of Pittsburgh, UNC, UM1, ACTG, Hook effect, Vesatolimod, Research, Toll-like receptor 7, Vaccine, University of Oxford, MVA, NIAID, University of North Carolina, Viral load, TLR7, Diagnosis, HIV, Immune system, Ageing

A5374 (Triple Immune Strategy for HIV Remission) is a multi-site, randomized, placebo-controlled trial.

Key Points: 
  • A5374 (Triple Immune Strategy for HIV Remission) is a multi-site, randomized, placebo-controlled trial.
  • After enrollment, participants will continue taking their HIV medications and will either receive a series of novel treatments or placebo.
  • Carefully monitored analytic treatment interruptions are an important part of HIV cure clinical trials.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., UNC (ACTG Vice-Chair).

Seyfarth Bolsters Corporate Department with Addition of Michael Delaney in Atlanta

Retrieved on: 
Mercoledì, Aprile 24, 2024
Legal, Professional Services, Corporation, University of North Carolina, Accounting, University, Master of Accountancy, Private practice, Georgia State University

Seyfarth Shaw LLP announced today the arrival of partner Michael Delaney to the firm’s corporate department.

Key Points: 
  • Seyfarth Shaw LLP announced today the arrival of partner Michael Delaney to the firm’s corporate department.
  • Delaney joins Seyfarth from Bryan Cave, where he was counsel in the corporate and finance transactions group.
  • “As we continue to strategically grow our national corporate department, and our foothold in Atlanta, we are thrilled to have Michael join us as our newest partner,” said Steven Kennedy , Seyfarth’s Atlanta office managing partner.
  • “Seyfarth’s comprehensive, business-driven approach, along with the strength of its corporate service offerings, provides an attractive platform to elevate my practice,” said Delaney.

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference

Retrieved on: 
Martedì, Aprile 16, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Rationale, University, Idiopathic pulmonary fibrosis, ATSF, ATS, Pulmonary hypertension, Route of administration, High Risk, PAH, Conference, Research, Electronic health record, Idiopathic disease, Orthostatic hypertension, University of North Carolina, Intelligence, Data, Pulmonary fibrosis, UTHR, Treatment, Doctor of Pharmacy, Inova Fairfax Hospital, University of Lagos, Prevalence, University of Florida, Creativity, American Thoracic Society, Medicine, PBC, Therapy, Theme, Incident, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024.
  • At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the company is sponsoring the ATS 2024 Women’s Forum.
  • “We look forward to presenting the latest data on several of our key products and development programs,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

YuJa Highlights First Quarter Progress, Product Innovations Designed to Improve Teaching and Learning

Retrieved on: 
Mercoledì, Aprile 10, 2024
Technology, Software, Audio, Video, Continuing, Training, University, Data Management, Primary, Secondary, Education, Artificial Intelligence, Learning, School, Utah Valley University, Zawar Farid, Digital, HTML, Smart speaker, Florida SouthWestern State College, Public service, Brunswick Community College, University of North Carolina, Platform, Higher, Automation, Website, Nursing

YuJa added dozens of higher education institutions to its platforms, including community colleges, universities, and statewide systems.

Key Points: 
  • YuJa added dozens of higher education institutions to its platforms, including community colleges, universities, and statewide systems.
  • YuJa signed systemwide agreements with the Tennessee Board of Regents and with the Colorado Community College System.
  • In addition, new YuJa Panorama add-ons were introduced, including a Smart Speaker, PDF Remediation Max, and a Website Accessibility Widget.
  • The YuJa Verity Test Proctoring Platform updates were centered on enhancing the user experience for test takers, proctors, and reviewers.

SEABOARD FOODS NAMES CHAD GROVES AS PRESIDENT AND CEO TO SUCCEED PETER BROWN AFTER RETIREMENT

Retrieved on: 
Lunedì, Marzo 25, 2024
High Liner Foods, Butterball, University, Treasurer, MBA, Marketing, University of North Carolina, National Pork Board, Retirement, Purdue University, Management

MERRIAM, Kan., March 25, 2024 /PRNewswire/ -- Seaboard Corporation (NYSE American: SEB) today announced that it has named Chad Groves as the next President and Chief Executive Officer of its pork division, Seaboard Foods LLC (Seaboard Foods), to succeed Seaboard Foods' current President and Chief Executive Officer, Peter Brown, who announced that he will be retiring, effective June 28, 2024.

Key Points: 
  • MERRIAM, Kan., March 25, 2024 /PRNewswire/ -- Seaboard Corporation (NYSE American: SEB) today announced that it has named Chad Groves as the next President and Chief Executive Officer of its pork division, Seaboard Foods LLC (Seaboard Foods), to succeed Seaboard Foods' current President and Chief Executive Officer, Peter Brown, who announced that he will be retiring, effective June 28, 2024.
  • Mr. Brown joined Seaboard Foods in January 2021 after more than 30 years of executive leadership experience in the protein industry, including leadership positions with Butterball and High Liner Foods.
  • Seaboard would like to thank Mr. Brown for his leadership of the organization over the past three years.
  • Before joining Seaboard Foods, Mr. Groves was most recently the Vice President of Sales – Retail & Foodservice at Trilliant Food & Nutrition LLC and, prior to that, Vice President of Field Sales – Foodservice at High Liner Foods.

Lawsuit Challenges NCAA's Prize Money Restrictions

Retrieved on: 
Martedì, Marzo 19, 2024
National Collegiate Athletic Association, Sport, Tennis, NCAA, District court, UNC, University, Life, Athlete, University of North Carolina, Partnership

The lawsuit asks a U.S. District Court to strike down the NCAA's restrictions on student-athletes' acceptance of prize money earned in non-NCAA competitions.

Key Points: 
  • The lawsuit asks a U.S. District Court to strike down the NCAA's restrictions on student-athletes' acceptance of prize money earned in non-NCAA competitions.
  • The NCAA's longstanding "amateurism" rules prohibit student-athletes from accepting prize money earned primarily through participation in non-NCAA competitions, such as the U.S. Open Tennis Championships, the U.S. Open Golf Championship, the U.S.
  • Reese does not seek money but aims to eliminate the NCAA's illegal and arbitrary restrictions," said Peggy Wedgworth, a Senior Partner at Milberg.
  • Through attorneys with Milberg and Miller Monroe & Plyler, Brantmeier is seeking an injunction prohibiting the NCAA from enforcing its anticompetitive and unlawful rules restricting student-athletes' acceptance of prize money earned in non-NCAA competitions.

ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication

Retrieved on: 
Mercoledì, Marzo 6, 2024
Infection, Chair, Bangladesh Technical Education Board, Mental health, Injection (medicine), University of Alabama, Rilpivirine, Fungal infection, NIAID, Arm, CROI, PWH, Quality of life, ACTG, Johnson & Johnson, Data monitoring committee, Conference, Health, University, ART, UM1, Male, DSMB, ViiV Healthcare, HIV, Failure, University of North Carolina, Vaccine

“ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Key Points: 
  • “ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
  • Participants received incentives and support to adhere to their daily oral medication to first achieve viral suppression and if successful, they were randomized to either receive long-acting injectable treatment every four weeks or continue taking daily oral medication.
  • The long-acting injectable treatment was more effective than the daily oral medication at maintaining virologic suppression and avoiding treatment-related discontinuation.
  • Twenty-eight participants receiving the long-acting injectable treatment experienced regimen failure (defined as virologic failure or treatment discontinuation), compared to 47 receiving daily oral medication.